Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rescinnamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A2 known ✓ | Q05940 | 1/20 | 0.81 |
| ▸ | MEN1 | O00255 | 13/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 13/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 6/20 | 0.81 |
| ▸ | HBB | P68871 | 5/20 | 0.81 |
| ▸ | MAPT | P10636 | 5/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.81 |
| ▸ | CASP1 | P29466 | 4/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rescinnamine SCHEMBL29365500 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1ALDH1A1 | |
| Rescinnamine SCHEMBL30401630 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1ALDH1A1 | |
| Rescinnamine SCHEMBL30401771 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1ALDH1A1 | |
| Rescinnamine SCHEMBL14379420 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1ALDH1A1 | |
| Rescinnamine SCHEMBL8261530 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1ALDH1A1 | |
| Rescinnamine SCHEMBL24164175 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1ALDH1A1 | |
| Rescinnamine SCHEMBL15592450 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1ALDH1A1 | |
| Rescinnamine SCHEMBL9382396 | 0.96 | MEN1 (0.93) | MEN1KMT2AKDM4ETDP1ALDH1A1 | |
| SCHEMBL13130009 | 0.95 | MEN1 (0.91) | MEN1KMT2AKDM4ETDP1ALDH1A1 | |
| SCHEMBL13130010 | 0.94 | MEN1 (0.89) | MEN1KMT2AKDM4ETDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3389 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710928-A2 | METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| EP-4076652-B1 | A PHARMACEUTICALLY ACCEPTABLE SALT OF ATRASENTAN FOR USE IN A METHOD OF TREATING IGA NEPHROPATHY | CHINOOK THERAPEUTICS INC (US) | 2025-12-03 | — | — | EP | claimed |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | CHINOOK THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025081046-A1 | ULTRA-HIGH DRUG LOADING INJECTABLE DRUG SUSPENSION OF HYDROPHOBIC DRUGS FOR LONG-TERM DRUG DELIVERY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2025-04-17 | — | — | WO | claimed |
| EP-4525857-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| US-20250082608-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2025-03-13 | — | — | US | claimed |
| CN-118975947-A | Preparation method of oil-absorbing fluffy washing-free hair-drying spray and product thereof | 上海纳米技术及应用国家工程研究中心有限公司 | 2024-11-19 | — | — | CN | claimed |
| EP-4448096-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | Singapore Health Services Pte. Ltd. (SG) | 2024-10-23 | — | — | EP | claimed |
| US-12121509-B2 | Methods of improving renal function | CHINOOK THERAPEUTICS, INC. (US) | 2024-10-22 | — | — | US | claimed |
| US-4396616-A | DIURETICS, ENZYME INHIBITORS | MERCK & CO., INC. (US) | 1983-08-02 | — | — | US | claimed |
| EP-0083923-A2 | Aminoacyl-containing dipeptide derivatives useful as antihypertensives | MERCK & CO. INC. (US) | 1983-07-20 | — | — | EP | claimed |
| EP-0081094-A1 | Substituted omega-amino-carboxymethyldipeptide antihypertensive agents | MERCK & CO. INC. (US) | 1983-06-15 | — | — | EP | claimed |
| EP-0079522-A1 | N-Carboxymethyl(amidino)lysyl-proline antihypertensive agents | MERCK & CO. INC. (US) | 1983-05-25 | — | — | EP | claimed |
| EP-0061186-A1 | Dipeptides containing thialysine and homologs as antihypertensives | MERCK & CO. INC. (US) | 1982-09-29 | — | — | EP | claimed |
| EP-0061187-A1 | Bicyclic lactams as antihypertensives | MERCK & CO. INC. (US) | 1982-09-29 | — | — | EP | claimed |
| EP-0049842-A2 | Substituted enantholactam derivatives, a process for the preparation and a pharmaceutical composition useful in the treatment of hypertension comprising the same, and intermediates | MERCK & CO. INC. (US) | 1982-04-21 | — | — | EP | claimed |
| EP-0049505-A2 | Substituted caprolactam derivatives, a process for preparing and a pharmaceutical composition containing the same, and intermediates | MERCK & CO. INC. (US) | 1982-04-14 | — | — | EP | claimed |
| EP-0046289-A2 | Substituted enantholactam derivatives as antihypertensives, a process for preparing and a pharmaceutical composition containing them, and intermediates | MERCK & CO. INC. (US) | 1982-02-24 | — | — | EP | claimed |
| EP-0046291-A2 | Substituted caprolactam derivatives as antihypertensives, process for preparing them, pharmaceutical composition containing them, and intermediates | MERCK & CO. INC. (US) | 1982-02-24 | — | — | EP | claimed |